Archive
557 articles, sorted by publication time.
This international program applies generative structural models to SLC transporter drug discovery, with the goal not of immediately producing answers for new drugs, but of shortening the trial-and-error distance in early molecular screening and design.
An early-stage clinical trial has added controlled-release niacin to standard treatment, with preliminary progression-free survival higher than historical controls; but before it can become a therapy, it still faces hurdles including small size, non-randomization, and safety monitoring.
Insilico and SK Biopharmaceuticals are pushing AI drug design into neuroimmune diseases, but the deal value is only a ceiling; the real test is whether the targets and molecules proposed by algorithms can hold up in complex human neurobiology.
This collaboration, worth up to $2.5 billion, pushes generative AI from “finding molecules faster” toward a harder question: in central nervous system diseases where neuroinflammation, degeneration, and rare diseases overlap, can algorithm-generated drug candidates pass the test of human biology?
Amazon Science has disclosed an AI agent-guided nanobody design workflow that screened wet-lab-confirmed binders from hundreds of thousands of candidate molecules. It is not a declaration of drug success, but it pushes one of the most frequently asked questions in biomedical AI into measurable molecular affinity.
This does not mean an “age-reversal drug” has arrived. Rather, a high-risk concept has begun undergoing human safety testing: if optic nerve cells can be reset in a limited way, the treatment logic for age-related diseases may also be forced to be reconsidered.
AstraZeneca is counting on this oral breast cancer therapy to open its next growth curve, but after supplemental data and a negative vote at an expert meeting, the FDA has extended its review, reminding the market that the speed of new oncology drugs must ultimately yield to the persuasiveness of the evidence.
Foundayo does more than move a popular weight-loss therapy from syringe to tablet; the FDA’s rapid approval under a priority review pilot program also brings efficacy, accessibility, and regulatory speed to the fore at the same time.
Another major AI drug discovery deal has emerged, but the real weight of such contracts lies not in the headline value, but in whether milestones can be realized step by step: from algorithms proposing molecules to human trials proving efficacy, a long path of biological validation still stands in between.
An Indian stock market note placed Sun Pharma, Aurobindo and other companies in Monday’s spotlight; the scientific information is limited, but it reflects the increasingly close links among drug supply, regulation and capital markets.
Primary sclerosing cholangitis progresses slowly and brutally, and traditional hard endpoints often make trials long, expensive, and difficult to conduct; how endpoints are being redefined is affecting whether new drugs can truly reach patients.
A broad-spectrum coronavirus vaccine designed with the help of artificial intelligence has reportedly completed its first human safety test; it is not a shortcut to ending the pandemic, but it brings the idea of “preemptively guarding against the next coronavirus” closer to the clinic.